Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

Core Viewpoint - Umecrine Cognition's drug candidate golexanolone shows promise in reversing neuroinflammation in a Parkinson's disease model, indicating its potential as a chronic treatment option [1][3]. Company Overview - Karolinska Development AB holds a 73% ownership stake in Umecrine Cognition prior to dilution, emphasizing its significant investment in innovative medical solutions [4]. - The company focuses on identifying and developing breakthrough medical innovations in the Nordic region, aiming to create and grow companies that advance these innovations into commercial products [5][6]. Research Findings - A preclinical study demonstrated that golexanolone completely reverses the activation of immune cells responsible for neuroinflammation in the brain, which is crucial for controlling voluntary movement and posture [3]. - The treatment with golexanolone not only reversed the increase of inflammation-promoting proteins but also provided robust protection against neuroinflammation as early as three weeks after disease onset [3]. - After nine weeks, golexanolone continued to counteract inflammation and aided in restoring protective immune cells, indicating a sustained effect on harmful brain inflammation [3]. Academic Collaboration - The study was conducted in collaboration with academic partners at Centro de Investigación Príncipe Felipe in Valencia, Spain, highlighting the importance of academic partnerships in advancing medical research [4].